In an Australian-first clinical trial aimed at protecting hearts from chemotherapy-induced cardiotoxicity, the drugOlaparibwas used,according to NSW Health & Medical Research.This trial, led by Sverdlov and the HMRI team, investigated Olaparib's potential to mitigate the effects of doxorubicin, a common chemotherapy drug that can cause heart damage.
Explanation:
Cardiotoxicity:
This refers to heart damage that can occur as a side effect of certain cancer treatments, particularly chemotherapy.
Doxorubicin:
A commonly used chemotherapy drug known for its cardiotoxic potential.
Olaparib:
A drug initially developed to treat ovarian cancer, but its potential to protect the heart from chemotherapy-induced damage is being explored in this Australian trial.
Sverdlov and HMR
These researchers are involved in the clinical trial, aiming to find ways to reduce the risk of heart damage in patients undergoing cancer treatment.
This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes.
RAC Price at posting:
$1.42 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)